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Opioid peptide 
In previous studies to determine whether chronic opiate administration might negatively feedback upon endogenous opioid systems in the 
CNS, investigators found no changes in steady-state concentrations of opioid peptides following morphine pelleting. However, since only 
steady-state levels were measured, it was still not clear whether morphine treatment altered the release and/or biosynthesis of opioid-containing 
neurons. The goal of the present study was to assess the effects of chronic morphine pelleting on the dynamics of fl-endorphin (fiE) biosynthesis 
in rats. Hence, at several times during a 7-day morphine treatment, concentrations of total flE-immunoreactivity (-it), as well as 
chromatographically sieved forms of fiE, were determined by RIA, and mRNA levels of pro-opiomelanocortin (POMC) were measured by 
a solution phase protection assay using a mouse or rat POMC 32p-labelled riboprobe. Concentrations of total flE-ir or different forms of flE-ir 
peptides (i.e. fl-lipotropin, flE1_31 , or flEl_27/flEl_26 ) in the hypothalamus or midbrain following either 1 or 7 days of treatment were similar 
in morphine- and placebo-pelleted animals. However, a significant increase in total hypothalamic flE-ir was observed following 3 days of 
morphine pelleting; chromatographic analyses indicated that this was primarily due to a selective increase in the opiate inactive forms of fiE, 
i.e. flEl_27/flEl_26. After 7 days of pelleting, morphine-treated animals tended to have lower POMC mRNA levels than those of placebo controls 
(20 to 50% decrease in different studies). The accumulation of hypothalamic flE-ir at 3 days, and the apparent decline in POMC mRNA levels 
at 7 days, lend support to the hypothesis that morphine negatively feeds back upon POMC neurons in the brain by inhibiting fiE release and 
biosynthesis. 
INTRODUCTION 
Over  the past 15 years, investigators have pondered 
whether the tolerance and/or dependence induced by 
chronic opiate administration might be related to alter- 
ations in endogenous opioid systems in the brain. Shortly 
after the discovery of the enkephalins, Kosterlitz and 
Hughes 2t hypothesized that chronic morphine treatment 
might result in agonist-induced feedback inhibition of 
endogenous opioid biosynthesis, a phenomenom well 
established in catecholamine systems 3°'31. Early studies 
designed to test this hypothesis found no changes in the 
immunoreactive concentrations of fl-endorphin (fiE) or 
the enkephalins following a short-term (3-10 days) 
morphine treatment which produces morphine tolerance 
and dependence 9'13'15,36. However,  these data were 
based solely upon steady-state peptide levels and pro- 
vided no information about the ' turnover rate '  of the 
endogenous opioids. Some measure of the relative rates 
of peptide synthesis, release, and degradation is essential 
to discriminate between systems which have increased, or 
decreased, rates of  both biosynthesis and release from 
those which have maintained established metabolic rates, 
since all 3 conditions could result in similar steady-state 
levels of peptide product. Thanks to the large increase in 
our understanding of peptide biosynthesis and to recent 
technological advances in molecular biology, we can now 
better estimate the dynamics of endogenous opioid 
biosynthesis. In the present studies, we re-examined the 
question of morphine 's  effects on brain opioid systems, 
focusing in particular on the pro-opiomelanocortin 
(POMC) opioid peptide family. 
POMC is the precursor protein of the potent opioid 
peptide flEl_31 as well as a number  of other bioactive 
peptides, including beta-lipotropin (fi-LPH), adrenocor- 
ticotropin (ACTH)  and a family of melanocyte-stimu- 
lating hormones (MSH's) (see refs. 12, 29 for reviews). 
In the CNS, the major  POMC cell group is situated in the 
arcuate nucleus of the medio-basal hypothalamus 7,33,34, 
with a second, smaller cluster of POMC cell bodies 
localized in the nucleus of the solitary tract (NTS) and 
nucleus commissuralis in the cadual medulla 19'2s. POMC 
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projections from the arcuate nucleus innervate a diverse 
number of brain regions, including various hypothalamic 
nuclei, the periventricular nucleus of the thalamus, limbic 
structures such as the septum and amygdala, and the 
periaqueductal gray (PAG) through the diencephalon 
and midbrain 17'18'33. Although projection areas of POMC 
neurons in the NTS have not been well documented, it is 
possible that the NTS and arcuate groups may share some 
common terminal fields. While flE1_31 is a major cleavage 
product of POMC in all tissues, it can undergo further 
modification by carboxy-terminal cleavage or N-terminal 
acetylation 2'11'12'37. Thus, full length flE1_31 and the 
carboxy-terminal shortened forms, flE1_27 and flE1_26 , 
can exist in N-acetylated or non-acetylated forms. In all 
brain regions studied, fiE1_31 is the major immunoreac- 
tive form of fiE, with smaller amounts of flEl_27 , and no 
fl-LPH, present 14'35. The great majority of flE-immuno- 
reactive (fiE-k) species in the brain are not acetylated. 
When the effects of chronic morphine treatment on 
brain levels of fiE-it were examined in earlier studies, 
investigators were unaware that at least 7 different 
peptides (fl-LPH, and N-acetylated or non-acetylated 
forms of flEl_31, flE1_27 and flE1_26) might be contributing 
to the total flE-ir detected. It is possible that chronic 
morphine treatment affects POMC processing in a way 
which would result in alterations in the concentrations of 
differently processed flE-ir peptides without changing the 
total amount of fiE-it. Alterations in the relative amounts 
of flEl_31 and flEl_27 could be physiologically significant 
since post-translational modifications of flEx_31 radically 
alter the opioid characteristics of the peptide. Carboxy- 
terminal shortened forms of flE1_31 are 10 times less 
potent than flE1_31 in displacing specific opiate binding 4 
and fail to produce analgesia 1°. There is also evidence to 
suggest that flEl_27 is antagonistic to the opiate effects of 
flEl_315"26. Hence, one question that was addressed in 
these studies was whether chronic morphine treatment 
might cause increased processing of flEl_al to flEl_27 , in 
effect reducing the intracellular concentration of endoge- 
nous opioid active material. 
While measurements of different immunoreactive 
forms of fiE are critical for understanding whether 
POMC processing might be altered following chronic 
morphine administration, they still represent steady-state 
concentrations and provide no information about the 
dynamics of the biosynthetic system (i.e. whether is has 
been activated or inhibited). The advent of molecular 
biological techniques which measure small amounts of 
POMC mRNA allowed us to determine a second param- 
eter of biosynthetic activity. The concomitant measure- 
ments of peptide and mRNA levels make it possible to 
infer information about the dynamics of biosynthetic 
systems and to more accurately assess whether neural 
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activity has been altered 27. For example, Costa and his 
colleagues, based upon data showing that levels of 
POMC mRNA and POMC precursor protein both 
declined by 30-50% following 5-7 days of morphine 
pelleting, concluded that chronic morphine causes down- 
regulation of POMC biosynthesis and utilization in the 
hypothalamus 23'24. It should be noted, however, that not 
all laboratories have detected changes in POMC mRNA 
levels following morphine treatment 16. 
Another issue to keep in mind when studying the 
possible effects of morphine treatment on endogenous 
opioid systems is that it is likely that cells engage in a 
series of responses in adapting to changes in their neural 
activity. An important lesson learned from studies in the 
pituitary gland (see, for example, ref. 3) is that peptide 
systems appear to be regulated by several mechanisms 
which act at different levels of the biosynthetic pathway 
(e.g., transcription, translation, precursor processing, 
post-translational modifications) at different times. Thus, 
it is possible that some parameters of brain POMC 
biosynthesis may be altered during the early stages of 
morphine treatment, but these alterations may disappear 
at later points in the treatment as other regulatory 
mechanisms become more important. Hence, examining 
the POMC system at several time points following 
morphine treatment may be necessary to observe the full 
sequelae of possible effects of opiate administration on 
fiE biosynthesis. In this paper, we attempted to provide 
a description of the effects of chronic morphine admin- 
istration on the dynamics of brain fiE biosynthesis by 
measuring different flE-ir peptide species and POMC 
mRNA levels in a cell body (arcuate nucleus) and nerve 
terminal (midbrain PAG) brain region at several time 
points following morphine pellet implantation. Pre- 
liminary results of these experiments have been re- 
ported 8. 
MATERIALS AND METHODS 
Animals 
Male Sprague-Dawley rats (Charles River Co., Wilmington, 
MA), weighing 220-250 g at the start of the experiments, were 
maintained in groups of 5-6 per cage, with free access to food and 
water, in an environmentally controlled room (12:12 h light:dark 
cycle, lights on at 06.00 h). 
Drug treatments 
Animals lightly anesthetized with ether were implanted under the 
skin between the scapula with morphine (75 mg) or placebo 
(containing avicel PH-102, magnesium stearate, silicon dioxide, and 
water) pellets (provided by courtesy of the National Institute of 
Drug Addiction). In the initial study, animals received a single 
morphine or placebo pellet on Day 1 and 3 additional pellets on Day 
4. On Day 7, morphine- or placebo-pelleted animals were injected 
i.p. with either naloxone (2.5 mg/kg) or saline vehicle and sacrificed 
30 min later. The 4 experimental groups were designated as: 
Placebo pellets/saline injection (PS); Placebo pellets/naloxone in- 
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jection (PN); Morphine pellets/saline injection (MS); Morphine 
pellets/naloxone injection (MN). In the time course studies, all 
animals had one morphine or placebo pellet implanted on Day 1. 
One set of placebo and morphine animals was sacrificed 24 h later, 
a second set was killed 72 h after pellet implantation, while a third 
set of animals was implanted with 3 additional (morphine or 
placebo) pellets on Day 4 and sacrificed on Day 7. Two brain 
regions were dissected and frozen immediately on dry ice: (1) a 
hypothalamic region which contains the major POMC cell body 
group in the arcuate nucleus as well as a widespread distribution of 
flE-ir terminals; and (2) a midbrain PAG region rich in flE-ir 
terminals derived primarily from the arcuate nucleus w'22. The 
hypothalamus was defined by the optic chiasm, the mammillary 
nuclei, the lateral aspects of the optic tract, and the top of the third 
ventricle - -  wet weight was roughtly 30-40 mg. The midbrain 
dissection simply involved coronal cuts anterior to the superior 
colliculi and posterior to the inferior colliculi - -  wet weight was 
approximately 115 mg. Total flE-ir was determined in the crude 
extracts of individual animals. Gel chromatography followed by fiE 
radioimmunoassay (RIA) was carried out on pooled samples from 
different experimental groups. POMC mRNA was quantitated by a 
solution phase-protection assay following extraction of nucleic acids 
from individual hypothalami. 
Gel chromatography 
Tissue was homogenized in acetone:0.2 N HCI (3:1) and the 
supernatant was dried down and resuspended in 1% formic acid 
containing 0.01% bovine serum albumin (BSA). After aliquots were 
removed for assay of total fiE-k, pooled extracts of 4-6 animals 
from each of the treatment groups were subjected to gel filtration 
chromatography to separate chemicals on the basis of molecular 
weight. Chromatography was carried out on a 1.5 x 90 cm Sephadex 
G-50-50 column developed with 1% formic acid containing 0.01% 
BSA. Fractions (1.3 ml) were collected and vacuum-dried for later 
assay for flE-ir. The column was precalibrated with blue dextran, 
cytochrome C, camel fiE 1 31, camel fiE l 27, and cobalt chloride. 
Peptide quantitation 
flE-ir in tissue extracts and chromatographic fractions was 
measured by RIA using an antibody directed primarily against the 
midportion of flEl_31 (i.e. flE17_27 ). At the concentration (1:40,000) 
used in this assay, and using 125I N-acetyl-flEl_27 as the radiolabelled 
tracer, the antibody was completely cross-reactive with fl-LPH, 
flEl_31 , flE1_27 , flEl_26 and their N-acetylated derivatives. The 
antibody showed no cross-reactivity with other POMC-derived 
peptides such as flEl_16 , flE1_17, Des- tyros ine  flEl_17 , flE27_31 , 
ACTHI_39, a-MSH or ),-MSH, nor did it cross-react with peptides 
from other opioid precursors (e.g. Leu-enkephalin, Met-enkepha- 
lin, dynorphin A, dynorphin B, a-neo-endorphin). Sensitivity of the 
assay under equilibrium conditions was 2-3 fmol per tube, with an 
ICso of approximately 20 fmol. Samples were resuspended in RIA 
buffer (150 mM Na phosphate buffer with 1% NaCI and 0.1% BSA, 
pH 8.2) and were quantitated relative to a camel fiE 1 31 standard 
curve. 
POMC mRNA quantitation 
POMC mRNA was quantitated in individual hypothalami of 
animals treated with placebo or morphine pellets for 3 or 7 days 
using a solution phase hybridization technique modified from Myers 
et al. 25. Total nucleic acids were extracted from hypothalami by 
homogenization in a LET buffer (10 mM Tris-HCl, pH 7.5, 10 mM 
EDTA, 1% lithium dodecylsulfate). After aliquots were removed 
for flE-ir determinations, extracts were incubated with 0.1% 
proteinase K for 60 min at 37 °C and nucleic acids were recovered 
by phenol/chloroform extractions followed by ethanol precipitation. 
Radiolabelled antisense cRNA POMC probes were produced by 
transcribing linearized SP64 or pGEM plasmids containing a mouse 
or rat POMC cDNA insert, using a-32p-cytosine triphosphate (CTP) 
as the radioactive label. The hybridization reaction was begun by 
incubating the radiolabelled cRNA and the extracted nucleic acids 
in a hybridization buffer (5x hybridization buffer: 0.2 M PIPES, pH 
6.4, 2.0 M NaCI, 5.0 mM EDTA) with deionized formamide for 5 
min at 90 °C and then for a minimum of 10 h at 50 °C. Single 
stranded RNA was digested by ribonuclease A (R-5125, Sigma, St. 
Louis, MO; 10/~g/ml in RNase buffer: 10 mM Tris-HCl, pH 7.5, 5.0 
mM EDTA, 0.2 M NaCI, 0.1 M LiCI) at 22 °C for approximately 60 
min. RNase activity was destroyed by Proteinase K (40 /~g/ml) 
treatment in 1% SDS at 37 °C for 30 min. Protected cRNA:mRNA 
hybrids were extracted with phenol/chloroform followed by ethanol 
precipitation and were fractionated by electrophoresis on 4% 
polyacrylamide non-denaturing gels in TBE buffer (89 mM Tris, 89 
mM boric acid, 2 mM EDTA). The gels were exposed via direct 
contact autoradiography on Kodak x-Omat XAR5 film and indi- 
vidual bands were quantitated by determining their total integrated 
optical density using a Loats Image Analysis System (Westminster, 
MD). 
Two different POMC cDNA sequences were used. A mouse 
cDNA (courtesy of Dr. J. Roberts) contained the coding region for 
most of CLIP and all of fl-LPH as well as approximately 100 bases 
of the 3" untranslated region which extended close to the poly- 
adenylation tail site. A rat clone (courtesy of Dr. J. Eberwine) 
corresponded to the 3" portion of Intron 2 and approximately 365 
bases of Exon 3 coding for amino acids 19-139 of the POMC 
precursor (i.e. ending just past the coding region of ACTHl_39 ). 
While there is roughly 93% homology between the 440 bases of the 
mouse riboprobe and the rat mRNA sequence, there are several 
sites where base mismatches are clustered together (Fig. 1A). 
Assuming that the RNase treatment was most likely to nick 
double-stranded RNA hybrids in regions in which there are 
non-complementary bases (i.e. in effect making these regions 
single-stranded), we anticipated that there would be more than one 
protected band when the mouse cRNA was hybridized against rat 
POMC mRNA. Since the 3" tail of the mouse probe had several 
base deletions and additions compared to the rat message, the 
longest protected hybrid that was predicted was approximately 390 
base pairs in length. In addition, we anticipated that protected 
hybrids corresponding to approximately 240, 210, 160 and 140 base 
pairs might be observed (Fig. 1A). There was a fairly good 
agreement between the predicted sizes of the protected bands (Fig. 
1B) and what was actually observed when the protection assay and 
gel electrophoresis was carried out (Fig. 1C). The two most intense 
bands corresponded to hybrids of approximately 350-370 and 240 
base pairs in length. In addition, there were fainter bands of roughly 
300, 180 and 150 base pairs in size. When the rat riboprobe was 
hybridized against rat POMC mRNA, only a single hybrid band was 
observed in autoradiographs of the electrophoresis gels (Fig. 1D). 
This band, estimated to be approximately 370 base pairs long, was 
fully predicted from the hybridization of the portion of riboprobe 
containing Exon 3 to the complementary region of the mRNA 
sequence, followed by RNase digestion of the single stranded 
intronic portion of the probe. 
Statistics 
Differences between experimental and appropriate control groups 
were statistically evaluated by 2-tailed t-tests using a significance 
level of 0.05. 
RESULTS 
Seven-day morphine~precipitated withdrawal: effects on 
fl E-ir peptides 
In t he  first  e x p e r i m e n t ,  we e x a m i n e d  t he  e f fec t  of  
ch ron i c  m o r p h i n e  p e l l e t i n g  o n  b r a i n  f i E - k ,  focus ing  in 
pa r t i cu l a r  on  w h e t h e r  t he  r e l a t i ve  c o n c e n t r a t i o n s  o f  the  
d i f f e ren t  f lE- i r  spec ies  m i g h t  b e  a l t e r e d  by  th is  p a r a d i g m .  
In a d d i t i o n ,  we w e r e  i n t e r e s t e d  in poss ib l e  c h a n g e s  in 
f lE- i r  p e p t i d e s  in m o r p h i n e - t o l e r a n t  a n i m a l s  w h o  w e r e  
A. PREDICTED HYBRIDS OF MOUSE cRNA AND RAT mRNA 
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Fig. 1. Predicted and observed bands of mouse cRNA:rat mRNA and rat cRNA:rat mRNA hybridization following RNase digestion. A: 
schematic representations of the corresponding rat mRNA and mouse cRNA sequences. Regions where base mismatches between the two 
sequences are concentrated are indicated in black. The predicted double stranded mouse cRNA:rat mRNA hybrids which would be protected 
from RNase digestion are indicated in the lower portion, assuming that RNase attacks and cleaves the full length (440 bp) hybrid at regions 
where base mismatches are clustered (i.e. in effect making these regions single stranded RNA's). Note that it is highly unlikely that the 3" 
portion of the mouse:rat RNA hybrid is protected from RNase attack because of the presence of a number of single base additions or deletions 
in the 3" terminus of the mouse sequence (checkered region) compared to the rat sequence; hence, the longest protected hybrid which was 
expected was roughly 390 bp. B: schematic of a theoretical autoradiograph based upon the protected fragments predicted in part A of this 
figure. C: observed autoradiograph of protected mouse cRNA:rat mRNA bands. The largest protected fragment (band 1) was estimated to 
be 350-370 bp while the most intense band (band 3) was approximately 240 bp in length. Minor bands (bands 2, 4, 5) corresponded to roughly 
300, 180 and 150 bp long, respectively. D: observed autoradiograph of protected rat POMC cRNA:rat mRNA hybrid. Note the presence of 
a single band corresponding to approximately 370 bp in length. M, morphine-pelleted animals; P, placebo-pelleted animals, XC, the position 
of the marker dye, xylene cyanol. 
undergoing naloxone-precipitated withdrawal. Total fiE- 
ir in crude extracts from the hypothalamus and midbrain 
was approximately the same in the 4 t reatment  groups 
(Fig. 2A,B).  The absence of changes in flE-ir in any of 
the brain regions examined was reinforced by chroma- 
tographic analyses. The chromatographic profiles of 
flE-ir from the PS, PN, MS and MN groups were 
extremely similar in both of the brain regions examined 
(Fig. 3). In each chromatograph,  3 main peaks of flE-ir 
were detected, which corresponded to the approximate 
106 
A .  











PS PN MS MN 
TREATMENT 
Fig. 2. Effect of 7 days of morphine treatment on concentrations of 
total flE-ir in A: hypothalamic and B" midbrain tissue extracts. 
Animals were implanted with 4 morphine (75 rag/pellet) or placebo 
pellets over a 7-day period and injected with either naloxone (2.5 
mg/kg) or saline vehicle 30 min before sacrifice, flE-ir was 
determined by RIA and is expressed as pmol fiE-it/rag tissue (wet 
weight). The 4 experimental treatments were: PS, placebo/saline; 
PN, placebo/naloxone; MS, morphine/saline; MN, morphine/nalox- 
one. Values represent the means + S.E.M. of 8 animals. 
TABLE I 
Effect of 7 days of morphine pelleting of POMC peptides in brain 
Total flE-ir in the two major peaks observed in the chromatographic 
profiles of Fig. 3. The two peaks corresponded to the elution 
positions of fiE 1 31 and flEl_27/flEl_26 (which could not be resolved 
from each other on this column). Values for fiE-it are expressed as 
pmol/peak. The ratios o f f l E l _ 3 1  tO t h e  flEl_27/flEl_26 peaks for the 4 
treatment conditions (see Fig. 2 legend) are shown in the last column. 
flEl_31 flEI_27/flEl_26 Ratio 
flEi_31:flEl_27/flEl_26 
Hypothalamus 
PS 4.41 3.32 1.3:1 
PN 4.65 3.82 1.2:1 
MS 4.69 3.41 1.4:1 
MN 4.70 3.41 1.4:1 
Midbrain 
PS 3.39 1.35 2.5:1 
PN 3.11 1.34 2.3:1 
MS 2.75 1.14 2.4:1 
MN 3.26 1.16 2.8:1 
elution volumes of fl-LPH, flEl_31 and flE1_27/flEl_26 (the 
chromatographic conditions used in these studies could 
not resolve flEl_27 from flE1_26 ). A small peak of 
immunoreactivity observed immediately after the void 
volume probably represents the precursor POMC. Total 
flE-ir associated with flEt_az- , and flE1_ET/flEl_26-sized 
peaks  did no t  di f fer  s ignif icantly b e t w e e n  the  4 t r e a t m e n t  
g roups  in the  two bra in  regions  e x a m i n e d  (Table  I). 
Three and seven days morphine treatment: effects on 
P O M C  m R N A  
In this e x p e r i m e n t ,  we  m e a s u r e d  the  effects  of  3 or  7 
days of  m o r p h i n e  pe l le t ing  on P O M C  m R N A  levels  in 
the  hypo tha lamus .  P O M C  m R N A  was quan t i t a t ed  in 2 
sepa ra te  s tudies,  using the  m o u s e  r i b o p r o b e  in S tudy 1 
and the  rat p r o b e  in S tudy 2. In Study 1, each  o f  the  5 
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Fig. 3. Chromatographic profiles of flE-ir in A: hypothalamic and B: midbrain extracts. Pooled samples of 4-8 animals from the 4 treatment 
groups (PS, PN, MS, MN; see legend to Fig. 2) were applied to a Sephadex G-50-50 column and developed with 1% formic acid containing 
0.01% BSA. Collected fractions (1.3 ml) were dried down and assayed for flE-ir. Values represent pmoi fiE-it/fraction. Arrows at the top of 
the chromatographs refer to the predicted elution positions of flE-ir peptides: 1, flLPH; 2, fiE] 3]; 3, fiE] 27/flE1_2.6 . 
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Study 1 Study 2 
Fig. 4. Effect of 7-day morphine treatment on POMC mRNA levels 
in the hypothalamus. Total nucleic acids from hypothalami of 
morphine- or placebo-pcl]eted animals were extracted in LET 
buffer. Following hybridization at 50 °C with a radiolabelled 
riboprobe complementary to either mouse (Study 1) or rat (Study 
2) POMC cDNA clones, 'unprotected' single-stranded RNA was 
digested by RNase A treatment. Protected cRNA:mRNA hybrids 
were extracted and fractionated on 4% polyacrylamide non- 
denaturing gels. Gels were exposed on Kodak x-OMAT XAR5 film 
and individual bands were quantitated densitometrically. The data 
for Study 1 shown in this figure were calculated for band 3 only (see 
Fig. 1C). Values represent the mean + S.E.M. of 5-6 animals and 
are expressed as a percent of the mean optical density of control 
animals. *P < 0.01 compared to placebo group. 
bands observed in the autoradiographs was densitome- 
trically analyzed (see Fig. 1C). In every case, the mean 
optical density of the bands of morphine-treated animals 
was lower than that of placebo-pelleted controls (al- 
though in the cases of Bands 1 and 2, this difference was 
not statistically significant). Quantitative analysis of the 
most intense hybrid band (Band 3) indicated that POMC 
mRNA levels in hypothalami from morphine-treated 
animals were approximately 50% lower than those seen 
in placebo-treated controls (t = 4.5, P < 0.01; Fig. 4). 
In Study 2, using the rat POMC cRNA, a single band 
was protected following RNase digestion (see Fig. 1D). 
Densitometric quantitation of this band revealed a small 
(approximately 20%) decrease in POMC signal in ani- 
mals morphine-treated for 7 days compared to placebo 
controls (Fig. 4), although this difference was not 
statistically significant. Similar amounts of POMC 
mRNA were detected in morphine and placebo animals 
following 3 days of treatment (data not shown). 
Morphine time course: effects on flE-ir peptides 
Although no changes in flE-ir peptide levels were 
found following 7 days of morphine treatment, the 
preceding data, showing that POMC mRNA tends to 
decline following chronic morphine, suggest the possibil- 
ity that f ie  biosynthesis might be reduced in morphine- 
pelleted animals. Hence, we re-examined the effect of 
morphine pelleting on flE-ir peptide levels at several time 
points over the 7-day treatment, reasoning that if 
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Fig. 5. Time course of effects of morphine pelleting on flE-ir 
concentrations in the A: hypothalamus or B: midbrain. Animals 
were implanted with one morphine or placebo pellet and sacrificed 
24 (I DAY) or 72 h (3 DAY) later; other groups of animals received 
one morphine or placebo pellet on Day 1, 3 more pellets on Day 4 
and were sacrificed on Day 7 (7 DAY). flE-ir was determined by 
RIA and is expressed as pmol flE-ir/mg tissue (wet weight). Values 
represent the mean + S.E.M. of 5-14 animals. *P < 0.05 compared 
to 3 DAY placebo group. 
morphine decreased the release of flE-ir peptides, it 
might result in an intraneuronal accumulation of flE-ir at 
some point following morphine administration. 
flE-ir concentrations in the hypothalami of morphine- 
treated animals were unchanged from control values 
following 1 day of pelleting but were significantly 
increased after 3 days of treatment (Fig. 5A). Interest- 
ingly, flE-ir concentrations after 7 days of morphine 
treatment were comparable to those found in animals 
who were morphine-pelleted for 3 days. However, the 
flE-ir content of placebo controls at 7 days post-pelleting 
increased relative to 1- or 3-day placebo control levels; 
hence, as observed previously, no significant treatment 
effect was detected at this time point. No significant 
differences between morphine- and placebo-treated ani- 
mals were observed in midbrain concentrations of flE-ir 
at any of the time points examined (Fig. 5B). 
When the relative amounts of different sized immu- 
noreactive peptides in the hypothalamus were analyzed, 
we found that the increase in total hypothalamic flE-ir 
observed in 3-day morphine-treated animals" appeared to 
be the result of a selective increase in flE1_27/flEl_26 (Fig. 
6A). The ratio of flE1_31:flEl_27/flE1_26 concentrations in 
placebo-treated animals (approximately 1:1) declined in 
morphine-treated animals (to roughly 1:2). In contrast to 
the hypothalamus, 3 days of morphine pelleting did not 
alter the relative amounts of fiE1_31 and flEl_ET/flEl_26 
found in the midbrain (Fig. 6B). Following 1 or 7 days of 
treatment, morphine- and placebo-treated animals dis- 
played similar chromatographic profiles of sieved hypo- 
thalamic or midbrain pools (data not shown). 
The distribution of flE-ir in the brain following 
morphine treatment was assessed in a different way by 
calculating the ratio of the flE-ir content in the hypo- 
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Fig. 6. Effect of 3 days of morphine pelleting on fiE-it chromatographic profiles in the A: hypothalamus and B: midbrain. Pooled samples 
of 5-6 morphine- or placebo-treated animals were developed on a Sephadex G-50-50 column with 1% formic acid containing 0.01% BSA. 
Collected fractions (1.3 ml) were dried down and assayed for flE-ir. Values represent pmol fiE-it/fraction. Arrows at the top refer to the elution 
positions of fiE standards: 1, flEl_31; 2, flEl_27. 
thalamus relative to that found in the midbrain. Follow- 
ing 1 or 7 days of pelleting, there were no differences 
between the morphine and placebo groups in hypotha- 
lamic to midbrain ratios of total flE-ir. However, the 
hypothalamus:midbrain flE-ir ratio increased from 2:1 in 
3-day placebo-treated animals to approximately 6:1 in 
morphine-pelleted animals. This indicates that morphine 
caused an apparent redistribution of flE-ir from nerve 
terminals in the midbrain to POMC cell bodies in the 
hypothalamus. 
DISCUSSION 
The main goal of these studies was to determine 
whether POMC biosynthesis was altered following 
chronic administration of the opiate agonist, morphine. 
By examining both peptide and mRNA levels, a more 
detailed description of the dynamics of POMC biosyn- 
thesis was provided compared to earlier reports, when 
steady-state tissue levels of total flE-ir were the sole 
measure taken. In agreement with the results of previous 
studies  6"15"23"24, total fiE+it in selected brain areas (i.e. the 
hypothalamus and midbrain) was not altered in animals 
treated for 7 days with morphine pellets or in morphine- 
treated animals undergoing naloxone-precipitated with- 
drawal. Furthermore, there does not appear to be any 
effect of chronic morphine treatment or precipitated 
withdrawal on the processing of the POMC precursor 
molecule as evidenced by the fact that the relative 
amounts of fl-LPH, flEl_31 and flEl_27/flEl_26 remained 
fairly constant across all treatment groups in the two 
brain regions examined. The sieving data support recent 
results showing that 4 days of morphine pelleting had no 
effect on the processing of flE-ir peptides in the hypo- 
thalamus or PAG 6. If one relied solely upon peptide 
measurements at the 7-day time point, the evidence 
would suggest that chronic morphine administration had 
no effect on the biosynthesis of POMC-derived peptides. 
When peptide levels were determined at different 
times over the course of the morphine treatment, an 
interesting result was observed in placebo-pelleted ani- 
mals. Hypothalamic concentrations of flE-ir in animals 
placebo-pelleted for 7 days were approximately twice as 
high as those found in animals implanted with placebo 
pellets for 1 or 3 days (see Fig. 5). At the present time, 
it is not known whether the elevated fiE-it concentrations 
in the 7-day placebo group resulted from increased 
biosynthesis following increased neural activity or was 
due to an accumulation of fiE-it subsequent to reduced 
peptide release. The most obvious explanation for this 
'placebo-pelleting' effect relates to differences in the 
handling of the placebo groups. Animals pelleted for 1 or 
3 days were anesthetized and pelleted only once, while 
those treated for 7 days underwent the pelleting proce- 
dure a second time (i.e. on Day 4). The fact that 
hypothalamic flE-ir increased in the 7-day placebo- 
pelleted group relative to the 1- or 3-day groups suggests 
that some factor(s) associated with the second exposure 
to the pelleting procedure affected f/E-containing neu- 
rons. We are presently investigating whether a second 
exposure to ether anesthesia alters hypothalamic fiE-ir 
levels relative to those found in animals anesthetized only 
once. Although the presence of the 'pelleting' effect 
precludes making meaningful comparisons about mor- 
phine's effects across different time points, valid com- 
parisons between morphine and placebo groups can be 
evaluated at a given time point. 
Keeping in mind the cautionary note just mentioned, 
we believe that the present studies did yield two pieces of 
data which lend support to the hypothesis that morphine 
inhibits fiE biosynthesis in the brain. First, the amount of 
POMC mRNA detected in animals implanted with 
morphine pellets for 7 days was reduced (by roughly 50% 
in Study 1 and 20% in Study 2) compared to placebo- 
treated controls. That we observed a significant effect in 
one study (using the mouse riboprobe) but not in the 
other (using the rat POMC cRNA) reflects the confusion 
that already exists in the literature about whether chronic 
morphine treatment reduces 23'24 or has no effect 16 on 
hypothalamic POMC message. The variability in the 
magnitude of this effect across different studies may 
indicate that other factors (e.g. stress) have not remained 
constant in the different studies. In this regard, it is 
intriguing to note that there have also been conflicting 
reports on the effects of chronic morphine treatment on 
pro-enkephalin mRNA levels in the striatum, with some 
groups reporting that it reduces 32 pro-enkephalin mRNA 
while others claim it has no effect  24. In future studies, it 
will be important to either eliminate or control for 
possible factors which might modulate morphine's effects 
on endogenous opioid systems. Although variable, the 
present results, together with earlier data  23'24, suggest 
that POMC mRNA levels tend to decline following 
chronic morphine pelleting, indicating that fiE biosyn- 
thetic capacity in the hypothalamus might be reduced 
following 7 days of morphine treatment. 
The second piece of evidence which indicates that 
morphine may inhibit brain POMC biosynthesis and 
neural activity is that although no changes in tissue 
content of fiE-ir were observed following 7 days of 
morphine pelleting, significantly higher levels of fiE-ir 
were detected in the hypothalami of 3-day morphine- 
pelleted animals compared to 3-day placebo-pelleted 
controls. While it is conceivable that the accumulation of 
fiE-it after 3 days of pelleting results from increased 
POMC biosynthesis, the fact that we observed no 
increases in POMC mRNA levels, or in any other 
parameter of fiE biosynthesis or release, argues strongly 
against this possibility. Our interpretation of these data is 
that morphine reduced fiE release from POMC neurons 
while peptide biosynthesis proceeded at a normal rate, 
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causing fiE-ir to gradually accumulate in the hypothala- 
mus. This explanation is supported by the fact that the 
hypothalamus:midbrain ratio of fiE-ir concentrations was 
3-fold greater in morphine- versus placebo-treated ani- 
mals, suggesting that fiE-ir was no longer being trans- 
ported to nerve terminals in the midbrain but was 
accumulating in POMC cell bodies in the hypothalami of 
morphine-pelleted animals. One could speculate that 
when morphine treatment was continued beyond 3 days 
(i.e. to 7 days), homeostatic mechanisms caused POMC 
mRNA levels to decline to a point where the rate of fiE 
biosynthesis once again matched the rate of fiE release. 
Under this new equilibrium between synthesis and 
release, steady-state peptide levels in tissues of 7-day 
placebo- and morphine-treated animals would not differ. 
Also consistent with the notion that the accumulation of 
hypothalamic fiE-ir after 3 days of morphine is due to 
inhibited peptide release is the finding that there was a 
relatively selective accumulation of smaller forms of fiE 
(i.e. fiEl_26/fiEl_27 ). It is generally believed that peptide 
processing is a time-dependent process; hence, post- 
translational modifications which occur later in the 
processing pathway (e.g. COOH-terminal cleavage of 
fiEl_31 , C-terminal amidation, or N-terminal acetylation) 
may not proceed fully to completion. This appears to be 
the case for conversion of fiEl_31 tO fiEl_27 and fiEl_26 , as 
suggested by the fact that this processing event normally 
occurs less than 50% of the time in the brain and, under 
some circumstances, can become a rate-limiting biosyn- 
thetic step 1. Thus, it seems likely that the accumulation 
of flEl_27/flE1_E6-ir is indicative of increased storage time 
in granules (as a result of decreased release), leading to 
fuller processing. However, other interpretations of how 
hypothalamic  flEl_E7/flEl_26 peptides increase following 3 
days of morphine treatment are possible. For example, 
the enzyme responsible for converting fiE1_31 to fiE1_27 
may be transiently activated by morphine treatment. 
In addition to altering fiE-ir peptide and POMC 
mRNA levels at different times during morphine admin- 
istration, there is some evidence suggesting that mor- 
phine may inhibit fiE release in the brain. First, concen- 
trations of fiE-it in the hypophyseal portal plasma, which 
are thought to reflect release from hypothalamic POMC 
neurons, declined by over 60% following i.v. adminis- 
tration of morphine and this effect was blocked by 
naltrexone 2°. Second, results from in vitro studies have 
shown that the basal and K+-stimulated release of fiE-ir 
from hypothalamic slices into the incubation media is 
decreased in tissue of morphine-pelleted animals com- 
pared to placebo-pelleted controls (Bronstein and Akil, 
unpublished observations). These data, while prelimi- 
nary, suggest that even though fiE-it levels appear to be 
comparable in morphine- and placebo-treated animals, 
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the pept ide  pools  in morphine- t rea ted  animals may be 
less susceptible to release,  or  may be differently regu- 
la ted,  than those of  control  animals. 
If it is substant ia ted that morphine  does feedback to 
inhibit  the biosynthesis of an endogenous  opioid system, 
the precise function of the down-regulated system in 
opia te  to lerance and withdrawal would have to be 
established.  The  finding that flEl_27/flEl_26 selectively 
accumulated in the hypothalami  after 3 days of morphine  
t rea tment  could have a profound physiological effect, 
since flEl_26 and flEl_27 are much less potent  pept ides  
than flEl_314'10 The  effects of  changing the relative 
amounts  of full length and processed flE-ir  pept ides  may 
not  be readily apparent  as long as opiate  receptors  are 
occupied by morphine.  However ,  once the exogenous 
opia te  is removed,  and activation of opiate  receptors  
becomes  dependen t  on endogenous  stores of pept ides ,  
the decrease in the relative amount  offlEl_31 could result 
in reduced op io id -media ted  responses.  It is possible that 
the decreased opioidergic  tone in POMC (and perhaps 
other  opioid)  neurons which may follow cessation of 
long-term opia te  t rea tment  could play a role in the 
expression of various withdrawal symptoms.  
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